← Back to patent-cliff list
Daridorexant hydrochloride
Tier C — Watch / tradeDaridorexant hydrochloride
Actelion Pharmaceuticals Ltd
Originator
2022
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：OX1R, OX2R
Brand：QUVIVIQ, Quviviq
Indications (approved)：Insomnia and sleep disorders
Regional status
US
Approved
2022-01-07
EU
Approved
2022-04-29
China
Approved
2025-06-17
Japan
Approved
2024-09-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Daridorexant hydrochloride?
Approved indications include: Insomnia and sleep disorders.
When does the Daridorexant hydrochloride patent expire?
No public expiry year is available for Daridorexant hydrochloride yet; this page updates once verified.
How do I get a quote for Daridorexant hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27